Resolution on affordability of medicines

The European Parliament's plenary session approved on 2 March 2017 a resolution calling for measures to improve the traceability of R&D costs, public funding and marketing expenditure in the context of rising prices of medicines.

The document highlights that new medicine prices across the European Union had risen throughout the years to the point of being unaffordable for many citizens and threatening the sustainability of national health care systems.

ESO: Background information: EU Options for Improving Access to Medicines http://www.europeansources.info/record/eu-options-for-improving-access-to-medicines/

EurActiv, 28.09.16: Parliament wants harmonised criteria for drug pricing and reimbursement http://www.euractiv.com/section/health-consumers/news/parliament-wants-harmonised-criteria-for-drug-pricing-and-reimbursement/

ESO: Background information: Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States http://www.europeansources.info/record/council-conclusions-on-strengthening-the-balance-in-the-pharmaceutical-systems-in-the-eu-and-its-member-states/

EurActiv, 03.03.17: EU Parliament demands clarity in public funding of drugs R+D http://www.euractiv.com/section/health-consumers/news/eu-parliament-demands-clarity-in-public-funding-of-drugs-rd/

---